Sionna Therapeutics announced a restructuring plan involving a 46% workforce reduction and the wind-down of its SION-719 add-on program to focus resources on advancing the SION-451 and SION-2222 dual combination into a Phase 2a proof-of-concept trial expected to initiate in Q1 2027. The company estimates aggregate restructuring charges of approximately $6.4 million, including $5.3 million for severance and $0.7 million for contract close-outs. Concurrently, the Board approved an option repricing effective September 17, 2026, reducing exercise prices to the closing stock price to retain employees. Chief Business Officer Caroline Stark Beer was terminated without cause on September 15, 2026, while other executives assumed expanded roles. Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for cystic fibrosis.

Sionna Therapeutics announced that its PreciSION CF Phase 2a trial of SION-719 failed to meet the primary endpoint, showing no significant sweat chloride reduction when added to standard of care. Consequently, the company will not advance SION-719 as an add-on therapy. However, a Phase 1 trial of SION-451 dual combinations met safety and pharmacokinetic objectives, identifying SION-451 plus SION-2222 as the preferred combination for further evaluation. With approximately $268.3 million in cash at the end of Q2, Sionna plans to preserve capital while determining next steps for its pipeline. The company operates in the biopharmaceutical industry, developing novel medicines for cystic fibrosis.

Sionna Therapeutics reported second quarter 2026 financial results on August 6, 2026. The company incurred a net loss of $29.9 million and spent $21.9 million on research and development, up from $15.4 million in the prior year period. General and administrative expenses rose to $10.6 million from $6.5 million. Cash, cash equivalents, and marketable securities totaled $268.3 million as of June 30, 2026, which management expects will fund operations into 2028. Clinically, the PreciSION CF Phase 2a trial for SION-719 and a Phase 1 dual combination trial for SION-451 are on track to report topline data in summer 2026. Sionna Therapeutics is a clinical-stage biopharmaceutical company developing treatments for cystic fibrosis.